BD has announced a $110 million investment to expand its production of prefillable syringes in the United States. The company will introduce Neopak Glass Prefillable Syringe manufacturing at its facility in Columbus, Nebraska.
The investment includes $100 million allocated to establish the Neopak Glass Prefillable Syringe production line at the Columbus site. Supply from this line is targeted to begin by mid-2026. An additional $10 million will be invested to enhance cannula manufacturing capabilities at the same location.
This expansion is expected to create approximately 120 new roles at the facility. In an earlier announcement, BD had committed over $35 million to expand prefilled flush syringe production at Columbus, which added 50 jobs.
The Columbus facility has been part of BD's global manufacturing network for more than 75 years. It houses vertically integrated cannula design and production operations.
BD aims to strengthen the pharmaceutical supply chain and accelerate the delivery of biologic and glucagon-like peptide-1 (GLP-1) drugs through this initiative. The Neopak platform is available in 1ml and 2.25ml formats and is designed to support various formulation needs, including high viscosity and delivery device compatibility. It integrates with autoinjectors to facilitate patient-centric drug delivery in clinical and home settings.
Patrick Jeukenne, BD Pharmaceutical Systems worldwide president, said, "As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support US-based drug delivery innovation and supply chain resiliency." He added, "This investment in Nebraska advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions."
These investments are part of BD's plan to invest more than $2.5 billion in US manufacturing over five years. By localizing Neopak Glass Prefillable Syringe production, the company seeks to enhance pharmaceutical supply chain resilience in the US as demand increases for biologics and combination products targeting chronic diseases.